FDA Approves Supplemental Application for Epidiolex by Jazz Pharmaceuticals
The FDA has approved a supplemental application for Epidiolex, which contains cannabidiol as its active ingredient.
Asset / Drug
Drug and asset intelligence for Epidiolex with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.